Subscribe
brexit_istock-531915594_altamira83
altamira83 / iStockphoto.com
19 November 2018Big Pharma

LSPN Europe 2018: UK has SPC opportunity post-Brexit, says Dentons lawyer

The UK has an excellent opportunity to adopt laws on supplementary protection certificates (SPCs) that will provide a “clearer” set of legislation post-Brexit, said French lawyer Marianne Schaffner, partner at Dentons.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
LSPN Europe 2018: Russian litigation and US second medical use
20 November 2018   The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.
Big Pharma
LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers
16 November 2018   Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.
Asia-Pacific
LSPN Europe 2018: Chinese filings impressive statement, says EPO director
15 November 2018   Last year, for the first time in European Patent Office history, a Chinese company filed the most European patent applications, making an “impressive statement” on what companies in the country are doing, according to Peter Albrecht.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

More on this story

Americas
LSPN Europe 2018: Russian litigation and US second medical use
20 November 2018   The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.
Big Pharma
LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers
16 November 2018   Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.
Asia-Pacific
LSPN Europe 2018: Chinese filings impressive statement, says EPO director
15 November 2018   Last year, for the first time in European Patent Office history, a Chinese company filed the most European patent applications, making an “impressive statement” on what companies in the country are doing, according to Peter Albrecht.

More on this story

Americas
LSPN Europe 2018: Russian litigation and US second medical use
20 November 2018   The strategies of generic makers in Russia have changed dramatically over the past few years, according to Natalia Gulyaeva, partner at Hogan Lovells.
Big Pharma
LSPN Europe 2018: SPCs—important but ‘phenomenally complicated’, say lawyers
16 November 2018   Supplementary protection certificates are hugely important to MSD’s business, according to Elena Böhles, assistant counsel at the pharmaceutical company, based in Hertfordshire, UK.
Asia-Pacific
LSPN Europe 2018: Chinese filings impressive statement, says EPO director
15 November 2018   Last year, for the first time in European Patent Office history, a Chinese company filed the most European patent applications, making an “impressive statement” on what companies in the country are doing, according to Peter Albrecht.

More features

Killing the golden goose of US drug innovation (Part I)
Buchalter brings in new partner to head up medtech
Trump’s march-in rights threat: Why pharma is rethinking collaborations
UK gets new IP minister following cabinet reshuffle
Barnes & Thornburg reveals five new IP leaders
Former PTAB judge joins Sterne Kessler
GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?